Assessment of demodex presence in acne-like rash associated with cetuximab

References

• Su X, Lacouture ME, Jia Y, Wu S. Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 2009;77:124–133.
   PubMed Web of Science ®Google Scholar
• Qi WX, Sun YJ, Shen Z, Yao Y. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials. J Chemother 2014;26:359–368.
   PubMed Web of Science ®Google Scholar
• Baima B, Sticherling M. Demodicidosis revisited. Acta Derm Venereol 2002;82:3–6.
   PubMed Web of Science ®Google Scholar
• Elston CA, Elston DM. Demodex mites. Clin Dermatol 2014;32:739–743.
   PubMed Web of Science ®Google Scholar
• Aylesworth R, Vance C. Demodex folliculorum and Demodex brevis in cutaneous biopsies. J Am Acad Dermatol 1982;7:583–589.
   PubMed Web of Science ®Google Scholar
• Vollmer RT. Demodex-associated folliculitis. Am J Dermatopathol 1996;18:589–591.
   PubMed Web of Science ®Google Scholar
• Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinical importance of Demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol 2004;31:618–626.
   PubMed Web of Science ®Google Scholar
• Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993;128:650–659.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf [last accessed 14 Jun 2016].
   Google Scholar
• Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010;18:509–522.
   PubMed Web of Science ®Google Scholar
• Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610–621
   PubMed Web of Science ®Google Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425–1433.
   PubMed Web of Science ®Google Scholar
• Ehmann LM, Ruzicka T, Wollenberg A. Cutaneous side-effects of EGFR inhibitors and their management. Skin Therapy Lett 2011;16:1–3.
   PubMedGoogle Scholar
• Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 2013;8:173–181.
   PubMed Web of Science ®Google Scholar
• Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011;22:524–535.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Cotliar J, Mitchell EP. Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park, N.Y.) 2007;21:17–21.
   PubMedGoogle Scholar
• Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151:238–241.
   PubMed Web of Science ®Google Scholar
• Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803–812.
   PubMed Web of Science ®Google Scholar
• Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390–5396.
   PubMed Web of Science ®Google Scholar
• Gerber PA, Kukova G, Buhren BA, Homey B. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology (Basel) 2011;222:144–147.
   PubMed Web of Science ®Google Scholar
• Chon SY, Hassler AA. Demodex inflammatory eruption due to epidermal growth factor receptor inhibitor therapy. Br J Dermatol 2016;174:686–687.
   PubMed Web of Science ®Google Scholar
• Jost M, Kari C, Rodeck U. The EGF receptor: an essential regulator of multiple epidermal functions. Eur J Dermatol 2000;10:505–510.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345–356.
   PubMed Web of Science ®Google Scholar
• Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013;5:199ra111
   PubMed Web of Science ®Google Scholar
• Clyti E, Sayavong K, Chanthavisouk K. Demodecidosis in a patient infected by HIV: successful treatment with ivermectin. Ann Dermatol Venereol 2005;132:459–461.
   PubMed Web of Science ®Google Scholar
• Seyhan ME, Karincaoglu Y, Bayram N, et al. Density of Demodex folliculorum in haematological malignancies. J Int Med Res 2004;32:411–415.
   PubMed Web of Science ®Google Scholar
• Román-Curto C, Meseguer-Yebra C, Cañueto J, et al. Demodicidosis simulating acute graft-versus-host disease after allogeneic stem cell transplantation in one patient with acute lymphoblastic leukemia. Transpl Infect Dis 2012;14:387–390.
   PubMed Web of Science ®Google Scholar
• Patrizi A, Bianchi F, Neri I. Rosaceiform eruption induced by erlotinib. Dermatol Ther 2008;21 Suppl 2:S43–S45.
   PubMed Web of Science ®Google Scholar
• Eilers RE Jr, Gandhi M, Patel JD, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010;102:47–53
   PubMedGoogle Scholar
• Grenader T, Gipps M, Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008;9:59–60.
   PubMed Web of Science ®Google Scholar
• Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657–670.
   PubMed Web of Science ®Google Scholar
• Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292–302.
   PubMed Web of Science ®Google Scholar
• Forton FM. Papulopustular rosacea, skin immunity and Demodex: Pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol 2012;26:19–28.
   PubMed Web of Science ®Google Scholar
• Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003;163:303–312.
   PubMed Web of Science ®Google Scholar
• Porta Guardia CA. Demodex folliculorum: its association with oily skin surface rather than rosacea lesions. Int J Dermatol 2015;54:e14–e17.
   PubMed Web of Science ®Google Scholar